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Purpose: BRCA1/BRCA2 germline mutations appear to enhance the platinum-sensitivity,
but little is known about the prognostic relevance of polymorphisms in BRCA1/BRCA2
in epithelial ovarian cancer (EOC). This study evaluated whether common variants of
BRCA1/BRCA2 are associated with progression-free survival (PFS) and overall survival (OS)
in patients with advanced stage sporadic EOC.
Experimental Design: The allelic frequency of BRCA1 (2612C>T, P871L-rs799917) and
BRCA2 (114A>C, N372H-rs144848) were determined in normal blood DNA from women
in Gynecologic Oncology Group protocol #172 phase III trial with optimally resected stage III
EOC treated with intraperitoneal or intravenous cisplatin and paclitaxel (C+P). Associations
between polymorphisms and PFS or OS were assessed.
Results: Two hundred and thirty-two women were included for analyses. African Amer-
icans (AA) had different distributions for the two polymorphisms from Caucasians and
others. For non-AA patients, the genotype for BRCA1 P871L was distributed as 38% for
CC, 49% for CT, and 13% for TT. Median PFS was estimated to be 31, 21, and 21 months,
respectively. After adjusting for cell type, residual disease, and chemotherapy regimen,
CT/TT genotypes were associated with a 1.40-fold increased risk of disease progression
[95% confidence interval (CI)=1.00–1.95, p=0.049]. After removing seven patients with
known BRCA1 germline mutations, the hazard ratio (HR) was 1.36 (95% CI=0.97–1.91,
p=0.073).The association between BRCA1 P871L and OS was not significant (HR=1.25,
95% CI=0.88–1.76, p=0.212). Genotype distribution of BRCA2 N372H among non-AA
patients was 50, 44, and 6% for AA, AC, and CC, respectively and there is no evidence
that this BRCA2 polymorphism was related to PFS or OS.
Conclusion: Polymorphisms in BRCA1 P871L or in BRCA2 N372H were not associated
with either PFS or OS in women with optimally resected, stage III EOC treated with cisplatin
and paclitaxel.
Keywords: BRCA, polymorphism, ovarian cancer, chemotherapy, prognosis
INTRODUCTION
The standard treatment for advanced epithelial ovarian can-
cer (EOC) begins with cytoreductive surgery followed by
chemotherapy consisting of platinum and taxane (1–3).
Although tumor response rate to this regimen is as high
as 70–80%, the majority of patients relapse within 2–3 years
(3, 4). Identification of biomarkers that predict resistance
to platinum/taxane-based chemotherapy may allow alterna-
tive therapeutic options to be considered for this high-risk
group (5).
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Most ovarian cancers are due to sporadic events and 8–10% are
attributable primarily to germline mutations in breast cancer 1
(BRCA1) or BRCA2 genes (6). BRCA1 and BRCA2 are considered
tumor suppressor genes, and loss-of-function mutations confer
a significantly increased risk of developing breast and ovarian
cancer (6). BRCA-associated ovarian cancer patients appear to dis-
play a better response to platinum agents as compared to sporadic
patients (7–11), likely due to a BRCA-deficient tumor having sub-
optimal DNA repair and enhanced sensitivity to DNA-damaging
drugs (12–14). In sporadic EOC, the inactivation of BRCA through
various mechanisms is common and studies in this setting have
demonstrated that low levels of BRCA1 mRNA or protein pre-
dict improved outcome following platinum-based chemotherapy
(15–18). Associations between BRCA1 and treatment outcome
have been reported in several solid tumors including lung and
colorectal cancers (19–21). Taken together, BRCA1 and BRCA2
appear to play critical roles in development of ovarian cancer and
modulation of chemotherapy responsiveness.
A number of polymorphisms have been identified in the
BRCA1 gene and P871L (rs799917) is one of the most com-
mon variants with a minor allele (T) frequency of 32% among
Caucasian cancer patients (22, 23). In the BRCA2 gene, N372H
(rs144848) which results in an amino acid change is the most
common polymorphism with a minor allele (C) frequency of
27% among Caucasian cancer patients (22). It is unclear if these
common variants in BRCA1 or BRCA2 genes impact therapeu-
tic efficacy and clinical outcome. The prognostic value of these
two most common variants in the BRCA1 and BRCA2 genes
was examined in normal DNA from women who participated
in Gynecologic Oncology Group (GOG) protocol #172, a phase
III trial where patients with stage III EOC were treated with
cisplatin+ paclitaxel (C+P).
MATERIALS AND METHODS
STUDY POPULATION
Patients in this study participated in a randomized phase III
trial, GOG#172, and had normal DNA available for genotyping.
Details regarding eligibility criteria, treatment, and end points, and
the survival advantage for women randomized to intraperitoneal
C+P compared with intravenous C+P for GOG#172 have been
reported elsewhere (28). Women on this study provided written
informed consent to participate in GOG#172 and provide a blood
specimen for research consistent with all federal, state, and local
requirements.
GENOTYPING
Genomic DNA was extracted from white blood cells recov-
ered from whole blood as described previously (29). BRCA1
P871L (rs799917) and BRCA2 N372H (rs144848) polymorphisms
were genotyped using a MALDI-TOF iPLEXTMGOLD assay
(Sequenom, San Diego, CA, USA).
STATISTICAL ANALYSIS
The genotype data were tested for Hardy–Weinberg equilib-
rium (HWE) using exact permutation test. Associations between
polymorphisms and clinical characteristics were assessed using
Wilcoxon rank-sum for continuous variables and using Pearson-
χ2 or Fisher exact test for categorical variables. Kaplan–Meier
procedure was used to estimate progression-free survival (PFS)
and overall survival (OS) by genotype. Hazard ratios were esti-
mated using a Cox regression model adjusted for prognostic
factors including cell type (clear cell/mucinous vs. other histo-
logic subtypes), residual disease status (gross vs. no gross), and
treatment regimen (intraperitoneal vs. intravenous). These vari-
ables were selected for adjustment based on previous GOG studies
(28–30). Previous studies demonstrated that the distributions of
polymorphisms in BRCA1 and BRCA2 varied by race (22), analy-
ses of PFS/OS were performed without African American (AA)
women (data shown) and with AA women (data not shown). As
some women in GOG#172 had a known germline mutation in the
BRCA 1 gene, PFS/OS analyses were performed with and without
these patients.
RESULTS
Patient characteristics for the 232 women in this study are shown
in Table 1 and are representative of that observed in the entire
GOG#172 protocol (28). Approximately 55% of the women had
intravenous (IV) C+P, with the remainder receiving IP therapy.
At the time of analysis, 148 patients had died, 55 women were alive
with no evidence of disease, and 29 were alive with documented
recurrence/disease progression. The median follow-up period for
those still alive was 87 months. Overall, the median PFS of this
population was 21.8 months and the median OS was 57.8 months.
BRCA1 P871L POLYMORPHISM (N = 232)
The BRCA1 P871L polymorphism was associated with race
(p< 0.001) but not with other clinical variables (Table 2). In par-
ticular, there was no difference in genotype distribution between
HGS and non-HGS tumors (p= 0.700). All seven AA women
exhibited the TT genotype. Among non-AA patients, the genotype
for P871L in BRCA1 was distributed as 38% for CC, 49% for CT,
and 13% for TT, consistent with HWE (p= 0.569). Median PFS
was 31, 21, and 21 months, respectively (log-rank test for CC vs.
CT/TT:p= 0.109, Figure 1). Median OS was 70,55,and 59 months
for CC, CT, and TT genotypes, respectively (log-rank test for CC
vs. CT/TT: p= 0.359). After adjusting for cell type, residual dis-
ease, and chemotherapy regimen, patients with CT/TT genotypes
vs. the CC genotype had an increased risk of disease progression
(HR= 1.40, 95% CI= 1.00–1.95,p= 0.049, Table 2), and a similar
risk of death (HR= 1.25, 95% CI= 0.88–1.76, p= 0.212, Table 3).
When the seven women with a known BRCA1 mutation were
removed from the analysis, the association between the BRCA1
P871L polymorphism and PFS (HR= 1.36, 95% CI= 0.97–1.91,
p= 0.073) was no longer statistically significant (Table 3). Sub-
group analyses stratified by histology (HGS vs. non-HGS), disease
residual (microscopic vs. gross) or treatment arm (IV vs. IP)
illustrated trends suggestive of a modest elevation in risk of disease
progression for women with the CT/TT vs. CC genotype in these
subgroups, but these associations were not statistically significant
(Figure 2).
BRCA2 N372H POLYMORPHISM (N = 228)
All six AA women exhibited the CC genotype in BRCA2 N372H
(Table 2) but the relationship between the N372H polymorphism
and race did not reach statistical significance in this study. Among
the non-AA patients, the genotype for this polymorphism was dis-
tributed as 50% for AA, 44% for AC, and 6% for CC (p= 0.381 for
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Table 1 | Clinical Characteristics (N =232).
No. (%)
Age (years)
<55 104 (44.8)
55–64 63 (27.2)
≥65 65 (28.0)
Median (range) 57 (32–83)
Race
White 213 (91.8)
Black 7 (3.0)
Other 12 (5.2)
GOG performance status
0 101 (43.5)
1 115 (49.6)
2 16 (6.9)
Cell type
Serous 178 (76.7)
Endometrioid 15 (6.5)
Clear cell (CC) 14 (6.0)
Mutinous (MU) 1 (0.4)
Other1 24 (10.3)
Tumor grade
1 23 (9.9)
2 92 (39.7)
3 or clear cell 117 (50.4)
Histology
HGS2 157 (67.7)
Non-HGS 75 (32.3)
Residual disease
Microscopic 97 (41.8)
Gross 135 (58.2)
Treatment3
IP Cis+P 105 (45.3)
IV Cis+P 127 (54.7)
1. Other histologic subtypes included: mixed epithelial, undifferentiated, transi-
tional cell, and adenocarcinoma, not otherwise specified.
2. HGS: high-grade (grade 2 or grade 3) serous tumor.
3. IP, intraperitoneal; IV, Intravenous; Cis, cisplatin; P, paclitaxel.
HWE) (Table 2). There was no evidence that the BRCA2 N372H
polymorphism was associated with PFS or OS (Figure 3; Table 2).
DISCUSSION
Both preclinical and clinical data suggest that alterations in BRCA1
or BRCA2 have prognostic value in ovarian cancer. Patients with
germline mutations have improved clinical outcomes following
the platinum chemotherapy (9–11, 31, 37). Increased sensitivity
to DNA-damaging anti-cancer drugs has been associated with
BRCA1 or BRCA2 functional loss involving germline mutations
or epigenetic changes. To extend these prior studies, we evalu-
ated the prognostic value of the two common polymorphisms
in BRCA1 and BRCA2 in GOG#172. Common polymorphisms
in BRCA1 P871L and BRCA2 N372H polymorphism were not
strongly associated with clinical outcome (PFS or OS) in patients
treated with C+P. Patients with the CT or TT vs. the CC genotype
in BRCA1 P871L had a modest increased risk of disease recurrence
attributable at least in part to the subset of GOG#172 patients with
a known germline mutation in BRCA1.
Several factors prompted our interest in the BRCA1 P871L and
the BRCA2 N372H polymorphisms. First, both of these polymor-
phisms are very common and if one of them was found to be
strongly associated with PFS or OS that biomarker would be able
to be reliably detected in a minimally invasive blood sample. Sec-
ond, relatively little is known about the biological, functional, and
clinical impact of these polymorphisms. For example, the func-
tional consequence of C→T transition in P871L in BRCA1 is
not well understood. It is hypothesized that a C→T transition
in this polymorphism alters the expression and/or function of
BRCA1 enhancing chemosensitivity and outcome similar to that
reported for ERCC1 (29, 34–36). The functional effects of BRCA1
P871L have been evaluated in breast cancer cell lines, and the
different genotypes had distinctly different levels of BRCA1 pro-
tein (39). Based on this finding we expected enhanced sensitivity
to platinum in women with the BRCA1 polymorphism. Several
studies examined the association between BRCA1 P871L polymor-
phism and risk of developing ovarian. While there were reports
that the P871L polymorphisms was associated with an increased
risk of developing ovarian cancer (23, 24), this correlation was
not confirmed based on large-scale studies (25, 26). In con-
trast, a recent study reported that this polymorphism (P871L)
was associated with a reduced risk of developing cervical cancer
(32). Among advanced gastric cancer patients treated with C+P,
the P871L polymorphism was associated with improved PFS and
OS (33).
Third, BRCA1 may have different roles in modulation
of responses to DNA-damaging drugs compared with anti-
microtubule drugs. It is proposed that BRCA1 mediates resistance
to platinum agents involving activation of NER, HR, and FA/BRCA
repair pathways and sensitivity to taxane-based chemotherapy
involving mitotic spindle arrest followed by JNK/SAPK mediated
apoptosis (16, 31, 37). Thus far most clinical studies have focused
on BRCA1 deficiency as a potential biomarker of response to plat-
inum chemotherapy but not as a marker of taxane resistance. The
potential contradictory effects of BRCA1 on the two most com-
mon agents used to treat advanced ovarian cancer make it difficult
to appreciate how alterations in BRCA1 mediate tumor response
in patients treated with a combination of C+P.
Recent studies on BRCA1/BRCA2 have concluded that a
germline mutation in BRCA1 or BRCA2 was associated with
improved survival in ovarian cancer patients and BRCA2 carriers
had the best prognosis (40–42). Some investigators have proposed
that BRCA1 and BRCA2 work at different stage in DNA damage
response and in DNA repair. BRCA1 is functional in both check-
point activation and DNA repair, whereas BRCA2 is a mediator of
the core mechanism of homologous recombination (HR) (43). In
the present study, we evaluated the N372H (rs144848) common
variant of BRCA2 and determined that this polymorphism was
not associated with PFS or OS. However, given the critical role that
BRCA2 plays in HR, the effect that germline mutation in BRCA1
or BRCA2 has on increasing a woman’s risk of breast and ovarian
cancer and the fact that half the high-grade serous ovarian cancers
have defects in HR (27, 44), other SNPs in BRCA1/BRCA2 may
have clinical relevance. For example, extensive linkage disequilib-
rium (LD) exists across the BRCA1 gene with only two blocks of
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Table 2 | Associations between the BRCA1 P871L or BRCA2 N372H Polymorphism and Clinical Characteristics.
BRCA1 P871L BRCA2 N372H1
CC CT TT AA AC CC
No. (%) No. (%) No. (%) p-Value No. (%) No. (%) No. (%) p-Value
Age in years (median) 56.9 56.4 55.3 0.369a 54.9 57.9 55.6 0.820a
Race
White 81 (38.0) 104 (48.8) 28 (13.2) <0.001c 106 (50.5) 91 (43.3) 13 (6.2) 0.155c
Black 0 (0) 0 (0) 7 (100) 6 (100) 0 (0) 0 (0)
Other 4 (33.3) 7 (58.3) 1 (8.3) 5 (41.7) 6 (50.0) 1 (8.3)
Performance status
0 34 (33.7) 53 (52.5) 14 (13.9) 0.461b 51 (51.0) 44 (44.0) 5 (5.0) 0.791b
1 or 2 51 (38.9) 58 (44.3) 22 (16.8) 66 (51.6) 53 (41.4) 9 (7.0)
Histology
HGS2 55 (35.0) 76 (48.4) 26 (16.6) 0.700b 79 (51.3) 66 (42.9) 9 (5.8) 0.961b
Non-HGS 30 (40.0) 35 (46.7) 10 (13.3) 38 (51.4) 31 (41.9) 5 (6.8)
Tumor residual
No gross 35 (36.1) 46 (47.4) 16 (16.5) 0.940b 48 (50.0) 42 (43.8) 6 (6.3) 0.944b
Gross 50 (37.0) 65 (48.2) 20 (14.8) 69 (52.3) 55 (41.7) 8 (6.1)
Treatment3
IP C+P 37 (35.2) 51 (48.6) 17 (16.2) 0.914b 52 (50.0) 46 (44.2) 6 (5.8) 0.889b
IV C+P 48 (37.8) 60 (47.2) 19 (15.0) 65 (52.4) 51 (41.1) 8 (6.5)
1Genotype in BRCA2 N372H not determined for four specimens; CC, clear cell; MU, mucinous.
2HGS, high-grade (grade 2 or grade 3) serous tumor.
3IP, intraperitoneal; IV, intravenous; C, cisplatin; P, paclitaxel.
aWilcoxon rank-sum test.
bPearson-χ2 test.
cFisher exact test.
FIGURE 1 | Disease progression-free survival (PFS) by BRCA1P871L
polymorphism.
common genetic variations. The P871L polymorphism provided
information regarding one LD block in the BRCA1 gene. Evalu-
ation of a polymorphism in the other LD block in BRCA1 (e.g.,
Q356R) would be an efficient strategy for accessing the potential
impact of all of the polymorphisms in the second LD block in the
BRCA1 gene on treatment efficacy and/or outcome.
The clinical value of genetic variants in terms of prognosis and
drug response are often more subtle than prognostic clinical fac-
tors making them more challenging to evaluate in cancer patients
(38). Broadly defined clinical groupings and heterogeneous treat-
ment regimens can have a strong influence on outcomes and mask
the effects of individual genetic variants. One of the strengths of
this study is that the population is relatively homogeneous. All
of the women had optimally debulked stage III EOC and were
uniformly managed as a result of their participation in a GOG
phase III treatment protocol. Evaluation of other common poly-
morphisms in DNA repair remains a viable area of research given
the role that DNA repair plays in drug sensitivity and resistance as
well as genomic chaos and poor outcome in solid tumors like EOC
(44) with high initial response rates to platinum and taxane-based
chemotherapy and poor long term survival with 10-year survival
rates approaching 10%.
In summary, common polymorphisms in BRCA1 (P871L) and
BRCA2 (N372H) were not associated with PFS or OS in women
with optimally resected, stage III EOC treated with C+P. This
study provides supportive evidence that germline mutations in
BRCA1 enhance sensitivity and PFS.
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Table 3 | Progression-free survival (PFS) and overall survival (OS) by BRCA1 P871L and BRCA2 N372H polymorphisms for patients treated with
cisplatin/paclitaxel-based chemotherapy.*
No. (%) PFS OS
HR 95% CI p-Value HR 95% CI p-Value
BRCA1 P871L
All patients
CC 85 (37.8) Referent Referent
CT 111 (49.3) 1.37 0.96–1.94 0.079 1.21 0.84–1.74 0.300
TT 29 (12.9) 1.53 0.93–2.51 0.092 1.39 0.82–2.33 0.220
CC+TT 1.40 1.00–1.95 0.049 1.25 0.88–1.76 0.212
By excluding seven cases with known brca1 mutations
CC 83 (38.1) Reference Reference
CT 108 (49.5) 1.32 0.93–1.88 0.123 1.21 0.84–1.76 0.304
TT 27 (12.4) 1.54 0.93–2.55 0.092 1.31 0.76–2.26 0.327
CC+TT 1.36 0.97–1.91 0.073 1.23 0.87–1.76 0.244
BRCA2 N372H
AA 117 (51.3) Referent Referent
AC 97 (42.5) 1.08 0.78–1.50 0.659 1.20 0.85–1.69 0.311
CC 14 (6.1) 0.81 0.42–1.57 0.533 0.76 0.36–1.59 0.462
AC+CC 1.03 0.75–1.42 0.844 1.13 0.80–1.58 0.492
Hazard ratio (HR) and 95% confidence interval (CI) estimated from Cox regression model adjusted for cell type, tumor residual, and type of treatment.
*Analysis limited to patients by excluding African American women.
FIGURE 2 | Adjusted hazard ratio (HR) of disease progression for CT/TT
vs. CC genotype in BRCA1P87 in women with optimally resected stage
III epithelial ovarian cancer stratified by treatment or residual disease.
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